Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,143
- Phase 21,065
- Phase 1821
- Phase 1/Phase 2445
- Phase 3424
- Phase 4238
- Phase 2/Phase 394
Top conditions
- Multiple Sclerosis341
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis141
- Type 1 Diabetes133
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals63
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California494
- Maryland196
- Alabama175
- Florida143
- Arizona140
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT05998642RecruitingPhase 2
Ibrutinib combo for newly diagnosed brain lymphoma
This trial tests a combination of ibrutinib, methotrexate, and rituximab for people with newly diagnosed primary CNS lymphoma who cannot have a stem cell transplant. It aims to see if this drug combination can effectively treat the disease.
Calgary, AlbertaAges 18 years+ - NCT05998928RecruitingPhase 2
BCMA-GPRC5D CAR-T for relapsed or refractory multiple myeloma
This trial tests a new cell therapy (CAR-T) that targets two proteins on myeloma cells for patients whose cancer has returned or not responded after at least three prior treatments. It aims to see if this therapy is safe and effective.
Wuhan, HubeiAges 18–75 - NCT06001814Recruiting
Mindfulness program for heart health in older adults with HIV
This study tests whether a mindfulness and behavior change program can help older adults with HIV improve their heart health. It combines phone-based coaching and text messages to reduce stress and manage heart risk factors like high blood pressure and diabetes.
Boston, MassachusettsAges 50 years+ - NCT06002659RecruitingPhase 1/Phase 2
CAR T therapy targeting CD20 for B-cell lymphoma
This study tests a new type of CAR T cell therapy that targets the CD20 protein on B-cell lymphoma cells. It is for people with certain types of B-cell lymphoma that have not responded to at least two previous treatments and who cannot use or have already tried the approved CD19 CAR T therapy.
StockholmAges Any age - NCT06002828Recruiting
Social and genetic factors in young adult cancer survivors
This study looks at how social and genetic factors affect the health and quality of life of young adults who have survived Hodgkin or non-Hodgkin lymphoma. It may help doctors better support survivors after treatment.
Anchorage, AlaskaAges 18 years+ - NCT06003192Recruiting
Screen Smart: Boosting HIV testing in teens
This trial tests a digital health tool to help increase HIV screening and prevention among teenagers visiting the emergency department. If you are 15 to 21 years old, you may be able to join and help improve how we offer these services.
Columbus, OhioAges 15–21 - NCT06003283RecruitingPhase 4
Reducing rituximab doses in rheumatoid arthritis
This trial compares two ways to reduce the amount of rituximab you take: one that gradually gives it less often based on time, and another that only gives it when your disease flares up. The goal is to see which approach keeps your arthritis under control while using less medication.
Merksem, AntwerpenAges 18 years+ - NCT06004349Recruiting
Genetic study of autoinflammatory diseases
This study looks for genes linked to autoinflammatory diseases like VEXAS syndrome. You or your family member can join by mailing in a blood or saliva sample to help researchers better understand these conditions.
New York, New YorkAges 1 month+ - NCT06004011Recruiting
Cancer workforce roles for people living with HIV
This study looks at a program to help people living with HIV take on cancer-fighting roles (like caregiving or support workers). It follows volunteers for 3 years and checks how well the program works for them and their community.
LusakaAges 15–39 - NCT06004154Recruiting
Imaging follow-up for giant cell arteritis patients
This study follows up patients with giant cell arteritis (Horton's disease) using MRI and ultrasound to see how the disease and treatment affect blood vessels over time. It aims to improve understanding of the condition and your imaging results.
ParisAges 50 years+ - NCT06004986RecruitingPhase 4
Lowering Dupilumab Dose in Controlled Eczema
This study looks at whether people with well-controlled eczema can safely lower their dose of dupilumab (an injected medication). It aims to see if a reduced dose still keeps eczema under control.
Amsterdam, North HollandAges 18 years+ - NCT06005246Recruiting
Munich ME/CFS Study for Young People
This study is tracking children, teens, and young adults (up to age 25) who developed ME/CFS after an infection. It aims to better understand the condition in younger people.
Munich, BavariaAges Up to 25 years - NCT06005870RecruitingPhase 2
Zanubrutinib with R-CHOP for newly diagnosed p53-positive DLBCL
This trial tests a new combination: zanubrutinib (a targeted pill) plus standard chemotherapy (R-CHOP) for people newly diagnosed with DLBCL whose cancer cells have high p53 protein levels. The goal is to see if adding this drug helps shrink tumors better than chemotherapy alone.
Wuhan, HubeiAges 18–75 - NCT06005298Recruiting
Testing SBIRT to help with PrEP and alcohol use
This study looks at whether talking about alcohol use can help people stick with their PrEP routine. It tests a simple program called SBIRT (Screening, Brief Intervention, and Referral to Treatment) to support your health and HIV prevention.
Louisville, KentuckyAges 18–85 - NCT06006117RecruitingPhase 3
Testing a new drug combination for relapsed marginal zone lymphoma
This trial compares a combination of mosunetuzumab and lenalidomide against standard treatments for people with marginal zone lymphoma that has come back or stopped responding to previous therapy. It aims to find out if the new combination works better than current options.
AnderlechtAges 18 years+ - NCT06006832Recruiting
A Study of Myasthenia Gravis in China
This study follows people with myasthenia gravis who are patients at Peking Union Medical College Hospital to learn more about the disease and how it affects patients over time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06007456Recruiting
Study of Juvenile Idiopathic Arthritis in Children
This study looks at children with arthritis to better understand their condition using clinical exams, lab tests, and ultrasounds. It may help doctors learn more about different types of juvenile arthritis.
TriesteAges Up to 18 years - NCT06008691Recruiting
Study of newer antibodies for B-cell lymphoma in Italy
This study watches how newer monoclonal antibodies (targeted therapies) work for people with B-cell non-Hodgkin lymphoma in real-world Italian clinics. It helps doctors learn more about how these treatments affect patients in everyday care.
Viagrande, CataniaAges 18 years+ - NCT06008808RecruitingPhase 1
Ruxolitinib and abatacept to prevent GVHD after haplo transplant
This trial tests whether a drug called ruxolitinib, with or without another drug called abatacept, can prevent graft-versus-host disease and cytokine release syndrome after a half-matched stem cell transplant from a family donor. It's for people with certain blood cancers who are getting this type of transplant.
St Louis, MissouriAges 18 years+ - NCT06010472RecruitingEarly Phase 1
Car-NK cell therapy for lupus
This trial tests a new immune cell therapy (CAR NK cells) for people with moderate to severe lupus that hasn't responded well to standard treatments. The therapy targets a protein called CD19 on certain immune cells to calm the overactive immune system.
ShanghaiAges 18–65 - NCT06013423RecruitingPhase 2
Cord blood transplant with chemo and radiation for high-risk blood cancers
This trial tests a cord blood transplant after a reduced-intensity chemotherapy and radiation regimen for patients with high-risk blood cancers like leukemia, lymphoma, or MDS. The goal is to see if this approach can help destroy cancer cells and restore healthy blood cells.
Seattle, WashingtonAges 6 months–65 years - NCT06013579Recruiting
Exercise study for older adults with HIV
This study tests whether high-intensity exercise can help improve thinking and memory, and build lasting exercise habits, in older adults living with HIV who feel tired and are not very active.
Birmingham, AlabamaAges 50–80 - NCT06014073RecruitingPhase 1/Phase 2
A new CAR-T cell therapy for relapsed B-cell lymphoma
This trial tests a special type of CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to standard treatments. The CAR-T cells are made from a donor and have genes removed to work better. The goal is to see if this treatment is safe and effective.
BeijingAges 18–70 - NCT06014879Recruiting
Strengths-based program for teens with type 1 diabetes
This study tests a program focused on your child's strengths to help manage type 1 diabetes. It is for youth ages 10 to 13 who have had diabetes for at least 6 months and a recent A1c of 7.5% or higher.
Houston, TexasAges 10–99
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,742 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.